Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in Mantle Cell Lymphoma
NCT05978739Phase 2Completed
- Sponsor
- InnoCare Pharma
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of orelabrutinib in mantle cell lymphoma (MCL) (2 arms), sponsored by InnoCare Pharma. Primary endpoint: Objective response rate at 2 years. Started Aug 2023; status: completed.
02
Drugs
orelabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05978739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978739.